Invalidity dossier
US 5168062
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
Current assignee: University of Iowa Research Foundation
Added 9/23/2026, 9:00:57 PM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview — US5168062A
Title: Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence.
Assignee: University of Iowa Research Foundation (UIRF). Inventor: Mark F. Stinski. Priority date: 1985-01-30. Application number: US07/582,130; filing date: 1990-09-10. Publication/grant date: 1992-12-01. Status: Expired – Lifetime; anticipated expiration 2009-12-01.
Purpose: The invention is exemplified by cloning a deoxynucleotide sequence possessing regulatory signals recognized preferentially by human cell factors involved in transcription by RNA polymerase II. This subject DNA sequence, or enhancer, provides a promoter-regulatory region to enhance expression of an adjacent gene in eucaryotic cells of human origin.
Plain-language scope (per the excerpt): The sequence derives from the human cytomegalovirus (HCMV) immediate-early (IE) region. Most viral RNA originates from HCMV's long unique component between 0.660 and 0.751 map units (Towne strain); the highly expressed IE region 1 (major IE gene) lies between 0.739 and 0.751 map units. The disclosure concerns transfer vectors (e.g., plasmids) and transformed host microorganisms carrying this promoter-regulatory DNA. General background describes enhancers influencing downstream expression in either orientation and at distances up to about 4 kilobases, and explains vectors, transformation, and expression concepts.
What the excerpt does not establish: It provides no claims text, no specific deposited accession numbers, no complete sequence listing, no detailed working examples or experimental data, no explicit definition of claim scope, and no prosecution history. Litigation entries, NIH confirmatory-license reassignments, and related family members (e.g., US5385839A) appear in the source metadata but fall outside this overview's permitted scope and are not assessed. No statement is made here regarding validity, enforceability, or prior art.
Source: https://patents.google.com/patent/[US5168062](/patent/US5168062)/en
Generated 10/1/2026, 9:41:01 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 5168062. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.